Brain stimulation improves motor control

Trial ID
NCT04799470
Official Title
Novel DBS Stimulation Patterns for Treatment of Parkinson's Disease - UNMC/Medtronic Collaborative Acute Feasibility Pilot
Goal
Brain stimulation improves motor control
Phase
NA
Status
RECRUITING
Sponsor
University of Nebraska
Study Type
INTERVENTIONAL
Enrollment
10 participants
Conditions
Parkinson's Disease
Interventions
Novel DBS stimulation patterns

Plain-Language Summary

The goal is to see whether new patterns of deep brain stimulation can better target the abnormal beta brain rhythms that underlie Parkinson's motor symptoms, potentially making stimulation more precise for people already helped by DBS. The approach tests novel timing and pulse patterns delivered through your existing Medtronic Percept PC, using the Percept BrainSense survey to detect a robust beta peak (≥ 0.7 µV/rtHz) and see how changing the stimulation pattern interacts with those rhythms while you remain on your usual DBS settings and medications. Adults 19 to 80 with idiopathic Parkinson's who already have bilateral STN DBS with a Percept PC, are at least 3 months post-op with optimized meds and settings, show a good clinical response and a detectable beta peak are eligible; people with implanted cardiac devices, unstable or unusual programming needs, or a Percept flagged for replacement are excluded.

Locations

  • Unversity of Nebraska Medical Center, Omaha, Nebraska, United States

Frequently Asked Questions

What is this trial testing?
This trial is studying Novel DBS stimulation patterns. The goal is to see whether new patterns of deep brain stimulation can better target the abnormal beta brain rhythms that underlie Parkinson's motor symptoms, potentially making stimulation more precise for people already helped by DBS. The approach tests novel timing and pulse patterns delivered through your existing Medtronic Percept PC, using the Percept BrainSense survey to detect a robust beta peak (≥ 0.7 µV/rtHz) and see how changing the stimulation pattern interacts with those rhythms while you remain on your usual DBS settings and medications. Adults 19 to 80 with idiopathic Parkinson's who already have bilateral STN DBS with a Percept PC, are at least 3 months post-op with optimized meds and settings, show a good clinical response and a detectable beta peak are eligible; people with implanted cardiac devices, unstable or unusual programming needs, or a Percept flagged for replacement are excluded.
Who can participate?
Participants must be between 19 Years and 80 Years.
Where is this trial located?
This trial is recruiting at 1 location.
Does it cost anything to join?
No. There is no cost to participate. Study-related care and treatment are provided at no charge.
How long does the trial last?
This trial is estimated to last approximately 4 years and 11 months.

View on ClinicalTrials.gov